Summary
A phase II single-blind, randomized, placebo-controlled trial to study the efficacy and safety of Study Drug administered as adjunctive treatment to patients with acquired thrombotic thrombocytopenic purpura.
Register to download
PRA Successfully Rescues Phase II Hematology Study
You may also be interested in:
Webcast
The Challenges of Patient Recruitment in Oncology Trials - Part 1
As the oncology environment continues to grow towards more targeted therapies, it is imperative that patient recruitment strategies focus on how to…
View Resource
Webcast
The Challenges of Patient Recruitment in Oncology Trials - Part 3
A Phase I through Phase III oncology trial costs approximately $56.3 million and lasts for eight years. In 2012, it was reported that a typical…
View Resource
page
Oncology
Our in-house oncology and hematology experts make the complex, simple. Our
Read More
View all related content and resources for Hematology
Explore Insights